# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug G...
Roth MKM analyst Jonathan Aschoff initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Targ...
HC Wainwright & Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $8 price tar...
GeoVax Labs received a BARDA Project NextGen award to conduct a study evaluating its COVID-19 vaccine candidate GEO-CM04S1.
- Bloomberg